Skip to main content
JCI Insight logoLink to JCI Insight
. 2016 Apr 21;1(5):e86375. doi: 10.1172/jci.insight.86375

Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis

Mark G Jones 1,2, Aurélie Fabre 3, Philipp Schneider 4, Francesco Cinetto 5, Giacomo Sgalla 1,2, Mark Mavrogordato 4, Sanjay Jogai 6, Aiman Alzetani 7, Ben G Marshall 2, Katherine MA O’Reilly 8,9, Jane A Warner 1, Peter M Lackie 1, Donna E Davies 1,2,10, David M Hansell 11, Andrew G Nicholson 12, Ian Sinclair 4, Kevin K Brown 13, Luca Richeldi 1,2,10
PMCID: PMC4889020  NIHMSID: NIHMS790182  PMID: 27275013

Abstract

In idiopathic pulmonary fibrosis (IPF), the fibroblast focus is a key histological feature representing active fibroproliferation. On standard 2D pathologic examination, fibroblast foci are considered small, distinct lesions, although they have been proposed to form a highly interconnected reticulum as the leading edge of a “wave” of fibrosis. Here, we characterized fibroblast focus morphology and interrelationships in 3D using an integrated micro-CT and histological methodology. In 3D, fibroblast foci were morphologically complex structures, with large variations in shape and volume (range, 1.3 × 104 to 9.9 × 107 μm3). Within each tissue sample numerous multiform foci were present, ranging from a minimum of 0.9 per mm3 of lung tissue to a maximum of 11.1 per mm3 of lung tissue. Each focus was an independent structure, and no interconnections were observed. Together, our data indicate that in 3D fibroblast foci form a constellation of heterogeneous structures with large variations in shape and volume, suggesting previously unrecognized plasticity. No evidence of interconnectivity was identified, consistent with the concept that foci represent discrete sites of lung injury and repair.


Integrated histological and microCT analyses reveal that 3D fibroblast foci are discrete structures with marked variations in shape and volume, suggesting previously unrecognized plasticity.

Introduction

Idiopathic pulmonary fibrosis (IPF) is the prototypic fibrotic lung disease in which progressive scarring of the lungs leads to death by respiratory failure (1). The median survival of 3 years from diagnosis is worse than many cancers (2). Despite identification of activated fibroblasts as key effector cells pathologically remodeling the extracellular matrix, therapeutic options remain limited, and a better understanding of disease pathogenesis is required (35).

Diagnosis of IPF is based on recognition of the usual interstitial pneumonia (UIP) pattern on chest high-resolution CT or surgical lung biopsy (1). The histological pattern of UIP is believed to be produced by the consequences of repeated epithelial injury together with unfettered fibroproliferation (6). Aggregates of proliferating fibroblasts and myofibroblasts, termed “fibroblast foci,” are a key histological diagnostic feature of UIP thought to represent areas of active fibrosis (7). On standard 2D pathologic examination fibroblast foci are considered small, distinct lesions, and their profusion has been reported to be of prognostic significance, although study findings vary (812). They have been proposed to be linked in a complex reticulum that is highly interconnected and extends from the pleura into the underlying parenchyma (13), yet the 3D morphology and spatial interrelationships of fibroblast foci remain poorly understood.

Micro-CT allows nondestructive imaging of tissue 3D microarchitecture, down to spatial resolutions, in the order of 1 to 10 μm (14, 15). It has informed our understanding of distal airways disease in patients with end-stage chronic obstructive pulmonary disease and chronic lung allograft rejection (16, 17). In fibrotic lung diseases, micro-CT imaging has been employed for quantification of fibrosis in small animal studies (1823); however, as samples have required processing with contrast agents or air inflation prior to fixation, application to diagnostic human interstitial lung disease (ILD) tissue samples has not been possible, with extremely limited tissue access. We have recently developed a protocol that allows imaging of routinely prepared formalin-fixed paraffin-embedded human lung tissue samples by micro-CT (24). This nondestructive process can be applied to tissue used for diagnosis, and conventional histopathologic sectioning of the tissue can subsequently be performed; this enables cellular or molecular information from methodologies such as immunohistochemistry or in situ hybridization to be precisely coregistered within the volumetric data set from micro-CT.

Given the pivotal nature of fibroproliferation to the progression of IPF and the key role that fibroblast foci are believed to play in this process (6), new insights into the structure of these lesions may further advance our understanding of whether they are interlinked in a complex reticulum as the leading edge of a “wave” of fibrosis or they comprise multiple distinct structures that have arisen as a consequence of multifocal lung injury (6, 13). In our study, we applied an integrated micro-CT and histological methodology on formalin-fixed paraffin-embedded diagnostic lung tissue to study the morphology of fibroblast foci in 3D. Our work demonstrates the potential for 3D imaging methodologies to further inform concepts of the underlying pathogenesis of fibrotic lung diseases and reveals that, in contrast to current understanding from standard pathology of 2D tissue sections, in 3D fibroblast foci form a constellation of heterogeneous structures, with large variations in shape and volume, suggesting previously unrecognized plasticity. We identify no evidence of general interconnectivity, consistent with the concept that foci represent discrete sites of lung injury and repair.

Results

Micro-CT of formalin-fixed paraffin-embedded lung tissue identifies diagnostic features of the UIP pattern.

First, we assessed visualization of diagnostic paraffin-embedded lung tissue 3D microarchitecture by micro-CT. Micro-CT enabled interactive multiplanar assessment of tissue microarchitecture (Supplemental Video 1; supplemental material available online with this article; doi:10.1172/jci.insight.86375DS1). 3D reconstructions identified clear morphological differences between normal and IPF lung tissue, with volume renderings in Figure 1 demonstrating loss of alveolar structures and increased parenchymal thickness in IPF, consistent with previous stereological findings (25). Supplemental Videos 2 and 3 visualize rotation of these volume renderings. Feature correspondence between corresponding histological sections and micro-CT slices of IPF lung tissue was assessed, with qualitative comparison (Figure 2) demonstrating that micro-CT can visualize normal lung structural features, such as airways, blood vessels, and alveolar airspaces, in addition to structural features of the UIP pattern, including heterogeneity of the distribution of interstitial fibrosis and normal appearing lung, architectural distortion, and honeycomb change.

Figure 1. 3D volume renderings of normal and usual interstitial pneumonia/idiopathic pulmonary fibrosis lung tissue imaged by micro-CT.

Figure 1

Cubes (2 mm per side) of (A) normal lung tissue and (B) usual interstitial pneumonia (UIP)/idiopathic pulmonary fibrosis (IPF) lung tissue were digitally extracted from the reconstructed micro-CT lung tissue volumes following removal of paraffin by absolute thresholding. For reference on the superior surface, a coregistered histological section stained with Movat’s Pentachrome is displayed. Morphological differences in 3D are apparent with UIP/IPF tissue, demonstrating loss of alveolar structures and increased parenchymal thickness, with an impression of “fullness” within the UIP/IPF tissue.

Figure 2. Correspondence of structural details identified by micro-CT to those seen by light microscopy.

Figure 2

(A and C) Registration-based image matching of a histological section of usual interstitial pneumonia/idiopathic pulmonary fibrosis tissue stained with Movat’s Pentachrome and (B and D) corresponding micro-CT images. Images in C and D are subareas of A and B. Scale bar: 1,400 μm (A and B); 500 μm (C and D).

Fibroblast foci are locally complex, heterogeneous structures in 3D.

We then studied whether fibroblast foci were identifiable in micro-CT image data. Correlation of histological slices and coregistered micro-CT images established features that typically enabled identification of fibroblast foci greater than 200 μm when integrated with visualization in 3 different planes (xy, xz, yz), specifically when the foci were adjacent to airspaces, given their reduced gray scale intensity when compared with surrounding tissue, as illustrated in Figure 3 and Supplemental Figure 1.

Figure 3. Multiplane visualization of a fibroblast focus with micro-CT.

Figure 3

(A) Movat’s Pentachrome stain of usual interstitial pneumonia/idiopathic pulmonary fibrosis tissue, with a fibroblast focus identified by the asterisk. The corresponding area of the micro-CT volume is seen in the xy plane in B. In addition, the focus can also be visualized (C) in the xz plane and (D) in the yz plane, enabling further assessment of the 3D morphology of fibroblast foci. Scale bar: 200 μm.

Initial visual 3-plane micro-CT analyses suggested a locally complex fibroblast focus morphology in 3D that was not apparent on cross-sectional 2D histopathologic examination. To confirm this finding, we performed histological identification of fibroblast foci, followed by segmentation of the corresponding image sections within the micro-CT volume to enable accurate integrated assessment of their 3D structure. Fibroblast foci were digitally labeled in the corresponding micro-CT slice every 8 μm over 1,000 μm, using the segmentation editor, having been identified in the histological sections as aggregates of spindle-shaped cells with a characteristic blue-green color on Movat’s pentachrome–stained sections or pale color on hematoxylin and eosin–stained sections; these stainings represent focal deposits of young, immature collagen and proteoglycans within the subepithelial interstitium. All foci within the micro-CT field of view were labeled. 3D visualization and quantification of the segmented data identified complex discrete structures with marked variation in size and shape (Figure 4, Table 1, Supplemental Figure 2, and Supplemental Video 4) that appear to be a nonuniform process. The 3D render visualized in Figure 4 is available for download (Supplemental Render 1).

Figure 4. Fibroblast foci are locally complex structures.

Figure 4

A computer-generated 3D surface view rendering of one fibroblast focus from micro-CT segmentation identifies that fibroblast foci are locally complex structures in 3D. The focus is blue, and for reference the pleural surface is visualized in yellow (height 1 mm) with a micro-CT slice shown inferiorly.

Table 1. Fibroblast focus measurements.

graphic file with name jciinsight-1-86375-g007.jpg

Fibroblast focus volumes ranged from 1.6 × 104 μm3 to 9.9 × 107 μm3. No evidence of substantial extension of individual foci inwards from the pleura to the parenchyma was identified. Review of digitally imaged sequential 2D histology sections identified the complex morphology of an individual fibroblast focus in 3D, with a number of apparently independent fibroblast foci in 2D identified to form one morphologically discrete structure. These foci ranged from relatively simple 3D structures (Supplemental Figure 3) to more morphologically complex structures adjacent to established fibrosis (Figure 5).

Figure 5. Review of coaligned Movat’s pentachrome–stained sections of an area of usual interstitial pneumonia tissue demonstrates the complex morphology of one fibroblast focus in 3D.

Figure 5

Following identification of one fibroblast focus (A, black arrow), (AM) illustrative photomicrographs demonstrate the changes in morphology of one fibroblast structure when sequential sections are visually reviewed, with apparently discrete foci forming part of one locally complex individual structure in 3D (indicated by black arrows in BM). In N and O, the focus is no longer visible. Section depth in microns is indicated for each photomicrograph. Scale bar: 500 μm. The 3D rendering of this fibroblast focus is visualized in Figure 4 and Supplemental Video 4.

Fibroblast foci are not generally interconnected.

Micro-CT 3-plane visualization, 3D segmentations (Figure 6 and Supplemental Video 5), and sequential 2D histology section review were evaluated for evidence of fibroblast focus interconnectivity at a larger scale, with numerous independent multiform fibroblast structures identified in each tissue volume and fibroblast focus frequency ranging from 0.9 to 11.1 per mm3 of lung tissue. The Euler number, a measure of redundancy in a network, was calculated for each case and identified no evidence of fibroblast focus interconnectivity (see Supplemental Table 1 and refs. 26, 27).

Figure 6. Fibroblast foci are discrete structures in 3D.

Figure 6

Computer-generated 3D surface view renderings of all fibroblast foci from two micro-CT segmentations. (A and C) Case 2 has the lowest number density of fibroblast foci per mm3 of lung tissue. (B and D) Case 3 has the highest number density. In A and B, a 3D surface view rendering is shown in the xy plane (corresponding to the histological sectioning plane) with tissue boundaries marked by the dashed gray lines. In C and D, a 3D surface view rendering is shown with a corresponding micro-CT slice displayed inferiorly (depth 1 mm). Scale bar: 2 mm.

Given the identified variability of foci in 3D, fibroblast focus profusion on 2D histological sections was then semiquantitatively and quantitatively assessed over a depth of 1 mm of lung tissue from each patient. Analyses identified variability both quantitatively (up to 4-fold intratissue variation) and semiquantitatively (Supplemental Figure 4). An exploratory analysis investigating the association between 3D fibroblast focus density and change in forced vital capacity (FVC) over 1 year identified a negative correlation (Supplemental Figure 5).

Discussion

Through an integrated histological and micro-CT analysis of IPF lung tissue we characterized fibroblast foci in 3D, identifying that they are morphologically complex structures with large variations in shape and volume. Within each tissue sample, numerous discrete fibroblast structures were present, without evidence of general interconnectivity.

While IPF remains an idiopathic disease, there have been several proposals regarding mechanisms of pathogenesis, one of which is that fibroblast foci form a highly complex and interconnected reticulum extending from the pleura to the lung parenchyma as a “wave” of progressive fibroproliferation (13, 28, 29). This concept was informed by a study from Cool et al., in which a computer-generated 3D reconstruction and Euler connectivity analysis of histological sections over a depth of 500 μm were proposed to demonstrate an interconnected fibroblast reticulum (13). However, the methodological advances of our work enabled analysis of far larger tissue volumes than previously possible, and we identified that the preceding reconstruction scale was consistent with visualization of one fibroblast focus of comparable dimensions to that shown in Figure 4. With multiple methodologies, our analyses showed that fibroblast foci are independent, discrete structures and, as a group, are not part of a reticulum. In support of this finding, human androgen receptor gene methylation assay analysis of foci by Cool et al. identified balanced methylation, indicating polyclonality of foci (13). Our results are consistent with the concept that fibroblast foci represent discrete nonconnected sites of localized lung injury, with 3D reconstructions identifying a constellation of independent fibroblast structures in support of the paradigm that IPF is a consequence of aberrant wound healing responses to local microinjuries (6).

At a 2D cross-sectional histological level, fibroblast foci are usually considered small, distinct lesions (7, 30), although they are often found grouped in proximity, forming what are thought to be areas of active fibrosis. Our results showed that, in 3D, foci in proximity and typically with shared areas of established fibrosis form one complex discrete fibroblast structure. A heterogeneous population was identified with large variations in size and shape and over a 100-fold difference between largest and smallest volume fibroblast foci. Acknowledging that the cause of lung injury in IPF has yet to be determined, we speculated a number of possibilities for this finding, which suggests previously unrecognized plasticity. It is possible that the size and morphology of an individual focus reflects the extent and distribution of injury at a lung surface. Alternatively, volume variation could indicate temporal growth of foci, with the smallest foci occurring at the most recent sites of injury. The latter possibility is in keeping with our identification of small isolated foci. Further work would be required to investigate these relationships in more detail.

While increased profusion of fibroblast foci has been proposed to correlate with mortality in patients with IPF, a number of studies have identified no association, and the clinical significance of this finding remains uncertain (812). Differences in patient selection and methodology have been suggested to account for discordant findings, with marked variations in methodologies, including semiquantitative scoring, quantitative point counting of random fields, or whole-slide fibroblast focus quantification. To our knowledge, no previous study has systematically assessed variability of foci within tissue samples. Our data indicated that fibroblast focus profusion can vary markedly over a 1-mm depth of tissue; however, studies correlating profusion with mortality have typically reviewed one or two tissue sections per lobe sampled. Focus variability within tissue samples should therefore be considered in future studies correlating fibroblast focus profusion with clinical outcome. In support of the concept of fibroblast foci as a marker of disease activity was our finding of a possible association between 3D fibroblast focus density and FVC change. However, given our limited sample size larger studies would be required to confirm such an association.

Although significant progress has been made, our understanding of the pathogenesis and treatment of IPF remains limited (6). Nintedanib and pirfenidone are two novel antifibrotic drugs that were recently shown to approximately halve the rate of decline of lung function in IPF (4, 5), with both having multiple actions on the proliferation and signaling pathways of fibroblasts and myofibroblasts (3134). Additional therapies are urgently required since these two drugs only reduce the rate of disease progression. This study emphasizes the importance of investigating new agents which prevent and/or ameliorate the repeated lung injuries that result in multifocal sites of fibroproliferation.

Initial work correlated micro-CT of whole paraffin-embedded samples of UIP tissue with histological sections. While soft tissue visualization through conventional X-ray–based CT is a challenge due to the low X-ray absorption of soft tissues, our micro-CT imaging protocol was optimized to provide the necessary image contrast between soft tissue and paraffin and also between different microarchitectural features within the tissue itself (24). Excellent microarchitectural feature correlation between histology and micro-CT imaging was observed, and diagnostic structural features of a pattern of UIP were visualized. Whereas larger fibroblast foci were directly visible within micro-CT image data, typically those less than 200 μm were not. In the future, identification and segmentation of smaller fibroblast foci may be possible through improved contrast resolution, thresholding, and pattern recognition approaches. Automated approaches, based on exploiting the X-ray attenuation contrast window between tissue and paraffin mounting medium as well as between different tissue compartments may further facilitate subsequent visualization and quantification.

There are significant advantages to the use of paraffin-embedded tissue to study fibrotic ILDs. While images of paraffin-embedded tissue have a lower contrast than air-inflated, fixed, and dried tissue samples, access to sufficient fresh or frozen diagnostic tissue with robust histopathological integration poses significant challenges in fibrotic ILDs. The availability of large banks of archived diagnostic paraffin-embedded samples facilitates systematic micro-CT analyses of fibrotic ILDs. Similarities and differences may further advance our understanding of underlying pathophysiology and potentially inform stratification approaches in fibrotic lung diseases. Given the diagnostic challenges that ILD histopathology poses, the ability to visualize in 3D could ultimately have diagnostic application. Furthermore, use of paraffin-embedded samples allows integration of coregistered histology sections within the 3D micro-CT volumetric data set; this enables accurate 3D analyses of the relationship of cellular and microarchitectural features of fibrotic lung diseases. While a predominantly manual segmentation methodology was applied during this initial study, development of automatic and semiautomatic methodologies will further enable quantitative feature extraction and analyses such as 3D topographical distribution of lung fibrosis.

Our study has demonstrated that the application of 3D imaging methodologies can further advance concepts of disease pathogenesis in fibrotic lung diseases. It has indicated that fibroblast foci are heterogeneous and of varying size, complexity, and frequency in each patient’s biopsy, suggesting previously unrecognized plasticity. We have also shown that these fibroblast structures are independent of each other, consistent with their being the product of discrete sites of lung injury and repair.

Methods

Clinical material.

Clinically indicated diagnostic surgical lung biopsy specimens from 4 patients (see Table 2 for further clinical details) with a subsequent multidisciplinary diagnosis of IPF according to international consensus guidelines were studied (1). No patient had clinical or radiological evidence of an acute exacerbation prior to or at the time of biopsy. Specimens had been diagnosed as showing a typical UIP pattern, confirmed by the independent review of two expert pulmonary pathologists. The samples had received standard processing with fixation in neutral buffered formalin for 48 hours and embedding in paraffin wax. Control formalin-fixed paraffin-embedded healthy lung tissue was from macroscopically normal lung sampled remote from the cancer site in two patients undergoing surgery for lung cancer.

Table 2. Patient demographics and longitudinal clinical data for the 4 subjects with usual interstitial pneumonia/idiopathic pulmonary fibrosis.

graphic file with name jciinsight-1-86375-g008.jpg

Micro-CT imaging protocol.

The paraffin-embedded lung samples were scanned using a custom-built Nikon Metrology micro-CT scanner at an isotropic voxel size of 8 μm as previously described (24), with optimization to maximize soft tissue contrast. An X-ray tube potential peak of 55 kVp was used at a beam current of 104 to 114 μA. 2,601 tomographic radiographic viewpoints of the samples were assessed (360° rotation in 0.14° steps) by acquiring 64 repeated projections (2,000 × 2,000 pixels) for each angular step to increase signal-to-noise ratio through frame averaging, where integration time for individual projections was set to 500 ms at an isotropic voxel size of 8 μm, resulting in a field of view of 16 × 16 mm2. Together with sample shuttling during acquisition to suppress ring artefacts with the reconstruction, the gross image acquisition time per sample was about 24 hours. The projections were then reconstructed in 3D using the Feldkamp, Davis, and Kress algorithm for cone beam tomography in the DigiR3D tomography reconstruction module of the DigiXCT software suite (Digisens) or using standard filtered-back projection within CTPro3D (v. XT 2.2 service pack 10, Nikon Metrology) and CTAgent (v. XT 2.2 service pack 10, Nikon Metrology) (35).

Histology acquisition.

Following micro-CT imaging 4-μm-thick serial sections were cut over an approximate depth of 1,000 μm. Sections every 8 μm (corresponding to the actual micro-CT voxel size of 8 μm) were deparaffinized and stained using modified Movat’s pentachrome or hematoxylin and eosin stain (36). Whole sections were imaged using a ×20 objective on a Dot-Slide scanning system (Olympus) and visualized with Olyvia 2.6 (Olympus).

Micro-CT image visualization and correlation with histological sections.

Image preprocessing, segmentation, 3D volume reconstruction, and quantification of lung sample micro-CT data were performed with AvizoFire 7.1 (FEI). Three or more structural features in each micro-CT volume were matched to a specific histological section, and the 3D orientation of the micro-CT volume was correspondingly transformed for plane correspondence between histological and micro-CT data. For direct comparisons of histological and micro-CT sections, the Fiji distribution of the ImageJ (version 1.49p) plugin Landmark Correspondences was used to coregister the images after the initial matching for plane correspondence (37, 38).

Micro-CT segmentation and analyses.

Fibroblast foci were digitally labeled in the corresponding micro-CT slice every 8 μm over 1,000 μm, using the segmentation editor, having been identified in the histological sections as aggregates of spindle-shaped cells by a characteristic blue-green color from Movat’s pentachrome stain or a pale color from hematoxylin and eosin stain; these stainings represent focal deposits of young, immature collagen and proteoglycans within the subepithelial interstitium. The contours of fibroblast foci within corresponding micro-CT slices were drawn using the “Lasso” function in AvizoFire. All foci within the micro-CT field of view were labeled. Missing levels (for example due to ribbon section breaks) were manually interpolated. Following tissue segmentation individual foci were then tagged by the labeling function, and individual foci were considered as separate structures if they had no common voxel faces, edges, or corners. The foci were then visualized through volume rendering using a cyclic color map so that foci in close proximity were more likely to be shown in a different color. Volume, 3D shape, and occurrence were quantified. For 3D volume renderings and calculation of lung tissue volume, paraffin was segmented from each micro-CT volumetric data set. Global thresholding was applied, followed by application of the “Smooth Labels” function of AvizoFire, with the threshold identified as the mean gray scale value of a 1-mm3 volume of paraffin. An example of these steps is shown in Supplemental Figure 6. Using the “Crop” function of AvizoFire, the subvolume corresponding to the histological stack was then extracted, and lung tissue volume quantified.

Fibroblast focus quantitation and connectivity analyses.

Connectivity between fibroblast foci was assessed visually through micro-CT 3-plane visualization, 3D foci segmentations, and corresponding sequential 2D histology section review. The total number of foci per case and fibroblast foci tissue density were calculated. Stereological analysis was performed, and fibroblast foci every 20 to 30 μm over approximately 1,000 μm were marked on photomicrographed whole-tissue sections using Olyvia. Fibroblast focus profusion was semiquantitatively (scale 0–6) or quantitatively (fibroblast foci per cm2 of tissue) measured on these sections. The Euler-Poincaré characteristic or Euler number (27, 39), a measure of redundancy in a network, was calculated. Full details are provided in the Supplemental Methods.

Statistics.

All graphs were created using GraphPad Prism software, and statistical analyses were calculated using GraphPad Prism (version 6; GraphPad Software). The correlation between 1 year FVC percentage change and fibroblast focus density was determined by linear regression. A P value of less than 0.05 was considered significant.

Study approval.

The study was approved by the Mid and South Buckinghamshire Local Research Ethics Committee (ref 07/H0607/73), and all subjects gave written informed consent.

Author contributions

MGJ, AF, PS, DED, and LR conceived the project, designed experiments, analyzed data, and wrote the manuscript. PML, JAW, KMAO, and IS contributed to the project conception, planning, and experimental design. MGJ, AF, GS, FC, MM, and SJ performed experiments and analyzed data. AA, BGM, and KMAO contributed to clinical sample collection. KKB contributed to data interpretation, data review, and manuscript revision. DMH and AGN contributed to the conception and design of the study and reviewed data. All authors reviewed, revised, and approved the manuscript for submission.

Supplementary Material

Supplemental data
Supplemental Video 1
Download video file (8.2MB, mp4)
Supplemental Video 2
Download video file (2.4MB, mp4)
Supplemental Video 3
Download video file (2MB, mp4)
Supplemental Video 4
Download video file (5MB, mp4)
Supplemental Video 5
Download video file (6.3MB, mp4)
Supplemental Render 1

Acknowledgments

This study was supported by a Wellcome Trust Clinical Research Training Fellowship (100638/Z/12/Z; to M.G. Jones). Infrastructure support was provided by the National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit. An Engineering and Physical Sciences Research Council (EPSRC) grant EP-H01506X is acknowledged for provision of the μ-VIS X-ray Imaging facilities. A.G. Nicholson and D.M. Hansell were supported by the NIH Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. We thank the staff of the NIHR Wellcome Trust Southampton Clinical Research Facility, the Biomedical Imaging Unit, the Histochemistry Research Unit, and the μ-VIS computed tomography centre at the University of Southampton.

Footnotes

Conflict of interest: M. Mavrogordato and I. Sinclair have received grants from Nikon Metrology outside of the submitted work. A.G. Nicholson has received personal fees from Sanofi outside of the submitted work. K.K. Brown has received research support from NIH/National Heart, Lung, and Blood Institute and personal fees from Boehringer Ingelheim and National Jewish Health outside of the submitted work. D.E. Davies has received personal fees from Synairgen outside of the submitted work. L. Richeldi has received personal fees from Boehringer Ingelheim and Roche outside of the submitted work.

License: This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Reference information:JCI Insight. 2016;1(5):e86375. doi:10.1172/jci.insight.86375.

Contributor Information

Aurélie Fabre, Email: A.Fabre@st-vincents.ie.

Francesco Cinetto, Email: francesco.cine@gmail.com.

Giacomo Sgalla, Email: G.Sgalla@soton.ac.uk.

Mark Mavrogordato, Email: mnm100@soton.ac.uk.

Sanjay Jogai, Email: Sanjay.Jogai@uhs.nhs.uk.

Aiman Alzetani, Email: Aiman.Alzetani@uhs.nhs.uk.

Andrew G. Nicholson, Email: a.nicholson@rbht.nhs.uk.

Ian Sinclair, Email: I.Sinclair@soton.ac.uk.

Luca Richeldi, Email: L.Richeldi@soton.ac.uk.

References

  • 1.Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi: 10.1164/rccm.2009-040GL. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3(1):e86375. doi: 10.1186/1750-1172-3-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012;122(8):2756–2762. doi: 10.1172/JCI60323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.King TE, Jr, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi: 10.1056/NEJMoa1402582. [DOI] [PubMed] [Google Scholar]
  • 5.Richeldi L, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. doi: 10.1056/NEJMoa1402584. [DOI] [PubMed] [Google Scholar]
  • 6.King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–1961. doi: 10.1016/S0140-6736(11)60052-4. [DOI] [PubMed] [Google Scholar]
  • 7.Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4):1301–1315. doi: 10.1164/ajrccm.157.4.9707039. [DOI] [PubMed] [Google Scholar]
  • 8.King TE, Jr, et al. Idiopathic pulmonary fibrosis — relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164(6):1025–1032. doi: 10.1164/ajrccm.164.6.2001056. [DOI] [PubMed] [Google Scholar]
  • 9.Nicholson AG, et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;166(2):173–177. doi: 10.1164/rccm.2109039. [DOI] [PubMed] [Google Scholar]
  • 10.Harada T, Watanabe K, Nabeshima K, Hamasaki M, Iwasaki H. Prognostic significance of fibroblastic foci in usual interstitial pneumonia and non-specific interstitial pneumonia. Respirology. 2013;18(2):278–283. doi: 10.1111/j.1440-1843.2012.02272.x. [DOI] [PubMed] [Google Scholar]
  • 11.Flaherty KR, et al. Fibroblastic foci in usual interstitial pneumonia. Am J Respir Crit Care Med. 2003;167(10):1410–1415. doi: 10.1164/rccm.200204-373OC. [DOI] [PubMed] [Google Scholar]
  • 12.Hanak V, et al. Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome. Respir Med. 2008;102(6):852–856. doi: 10.1016/j.rmed.2008.01.012. [DOI] [PubMed] [Google Scholar]
  • 13.Cool CD, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med. 2006;174(6):654–658. doi: 10.1164/rccm.200602-205OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Paulus MJ, Gleason SS, Kennel SJ, Hunsicker PR, Johnson DK. High resolution X-ray computed tomography: An emerging tool for small animal cancer research. Neoplasia. 2000;2(1-2):62–70. doi: 10.1038/sj.neo.7900069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Metscher BD. MicroCT for developmental biology: a versatile tool for high-contrast 3D imaging at histological resolutions. Dev Dyn. 2009;238(3):632–640. doi: 10.1002/dvdy.21857. [DOI] [PubMed] [Google Scholar]
  • 16.McDonough JE, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567–1575. doi: 10.1056/NEJMoa1106955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Verleden SE, et al. The site and nature of airway obstruction after lung transplantation. Am J Respir Crit Care Med. 2014;189(3):292–300. doi: 10.1164/rccm.201310-1894OC. [DOI] [PubMed] [Google Scholar]
  • 18.Scotton CJ, et al. Ex vivo micro-computed tomography analysis of bleomycin-induced lung fibrosis for preclinical drug evaluation. Eur Resp J. 2013;42(6):1633–1645. doi: 10.1183/09031936.00182412. [DOI] [PubMed] [Google Scholar]
  • 19.Ask K, et al. Comparison between conventional and “clinical” assessment of experimental lung fibrosis. J Transl Med. 2008;6(1):e86375. doi: 10.1186/1479-5876-6-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rodt T, et al. Micro-computed tomography of pulmonary fibrosis in mice induced by adenoviral gene transfer of biologically active transforming growth factor-b1. Respir Res. 2010;11(1):e86375. doi: 10.1186/1465-9921-11-181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cavanaugh D, et al. Quantification of bleomycin-induced murine lung damage in vivo with micro-computed tomography. Acad Radiol. 2006;13(12):1505–1512. doi: 10.1016/j.acra.2006.08.011. [DOI] [PubMed] [Google Scholar]
  • 22.De Langhe E, et al. Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography. PLoS One. 2012;7(8):e86375. doi: 10.1371/journal.pone.0043123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Shofer S, Badea C, Auerbach S, Schwartz DA, Johnson GA. A micro-computed tomography-based method for the measurement of pulmonary compliance in healthy and bleomycin-exposed mice. Exp Lung Res. 2007;33(3–4):169–183. doi: 10.1080/01902140701364458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Scott AE, et al. Three dimensional imaging of paraffin embedded human lung tissue samples by micro-computed tomography. PLoS One. 2015;10(6):e86375. doi: 10.1371/journal.pone.0126230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Coxson HO, et al. Quantification of idiopathic pulmonary fibrosis using computed tomography and histology. Am J Respir Crit Care Med. 1997;155(5):1649–1656. doi: 10.1164/ajrccm.155.5.9154871. [DOI] [PubMed] [Google Scholar]
  • 26.Ochs M, et al. The number of alveoli in the human lung. Am J Respir Crit Care Med. 2004;169(1):120–124. doi: 10.1164/rccm.200308-1107OC. [DOI] [PubMed] [Google Scholar]
  • 27.Gundersen HJ, et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS. 1988;96(10):857–881. doi: 10.1111/j.1699-0463.1988.tb00954.x. [DOI] [PubMed] [Google Scholar]
  • 28.Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Resp J. 2010;35(3):496–504. doi: 10.1183/09031936.00077309. [DOI] [PubMed] [Google Scholar]
  • 29.Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med. 2012;136(6):591–600. doi: 10.5858/arpa.2011-0511-OA. [DOI] [PubMed] [Google Scholar]
  • 30.Katzenstein AL, Myers JL, Prophet WD, Corley LS, Shin MS. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study. Am J Surg Pathol. 1986;10(6):373–381. doi: 10.1097/00000478-198606000-00002. [DOI] [PubMed] [Google Scholar]
  • 31.Conte E, et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–19. doi: 10.1016/j.ejps.2014.02.014. [DOI] [PubMed] [Google Scholar]
  • 32.Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;289(1):211–218. [PubMed] [Google Scholar]
  • 33.Rangarajan S, et al. Novel mechanisms for the anti-fibrotic action of nintedanib. Am J Respir Cell Mol Biol. 2016;54(1):51–59. doi: 10.1165/rcmb.2014-0445OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Anti-fibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor, nintedanib, in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349(2):209–220. doi: 10.1124/jpet.113.208223. [DOI] [PubMed] [Google Scholar]
  • 35.Feldkamp LA, Davis LC, Kress JW. Practical cone-beam algorithm. J Opt Soc Am A Opt Image Sci Vis. 1984;1(6):612–619. doi: 10.1364/JOSAA.1.000612. [DOI] [Google Scholar]
  • 36.Russell HK. A modification of Movat’s pentachrome stain. Arch Pathol Lab Me. 1972;94(2):187–191. [PubMed] [Google Scholar]
  • 37.Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Meth. 2012;9(7):676–682. doi: 10.1038/nmeth.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Saalfeld S, Cardona A, Hartenstein V, Tomancak P. As-rigid-as-possible mosaicking and serial section registration of large ssTEM datasets. Bioinformatics. 2010;26(12):i57–i63. doi: 10.1093/bioinformatics/btq219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Nyengaard JR, Marcussen N. The number of glomerular capillaries estimated by an unbiased and efficient stereological method. J Microsc. 1993;171(pt 1):27–37. doi: 10.1111/j.1365-2818.1993.tb03356.x. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental data
Supplemental Video 1
Download video file (8.2MB, mp4)
Supplemental Video 2
Download video file (2.4MB, mp4)
Supplemental Video 3
Download video file (2MB, mp4)
Supplemental Video 4
Download video file (5MB, mp4)
Supplemental Video 5
Download video file (6.3MB, mp4)
Supplemental Render 1

Articles from JCI Insight are provided here courtesy of American Society for Clinical Investigation

RESOURCES